We explored venture capitalists’ latest bets on fertility and contraception tech, including Modern Fertility, Extend Fertility, Natural Cycles, Nurx, Clue and more.
View More It’s a new era for fertility tech
23andme
Afton Vechery
Birth Control
boxgroup
Carrot
Clue
Deborah Anderson-Bialis
eqt ventures
femtech
fertilityIQ
First Round Capital
Glow
Health
Ida Tin
instagram
Kleiner Perkins
LinkedIn
Lowercase Capital
maveron
Max Levchin
Mike Huang
Modern Fertility
Mosaic Ventures
Natural Cycles
nea
Nurx
partner
Rebecca Kaden
San Francisco
sequoia capital
Softbank
sound ventures
stockholm
Telemedicine
Venture Capital
Vision Fund
Womens Health
Y Combinator


Fitbit’s first smartwatch had its fair share of issues, including a large size, which made it unwieldy for many wrists. That fact no doubt automatically excluded the product from a big chunk of its potential user base, including a lot of women. Fitbit’s hardly alone among wearable makers in that oversight, of course, but the issue certainly stood out for a company whose products…
At-home health testing kits are all the rage now. You can get them to analyze your genetic makeup, test for STDs and food sensitivity, and even tell you about your ovarian reserve. As TechCrunch’s in-house guinea pig, I decided to take EverlyWell’s ovarian reserve test for a spin. An ovarian reserve test evaluates your egg quality and quantity. EverlyWell describes it as a test to…
Unbound, a sexual wellness startup for women, recently raised $2.7 million from Founders Fund, Slow Ventures, Arena Ventures, SoGal Ventures and others. Founded by Polly Rodriguez of Women of SexTech, Unbound aims to empower women to own their sexuality. “Raising money is always hard but it took an exceptional amount of resilience,” Rodriguez said. Unbound’s bread and butter… /https%3A%2F%2Fblueprint-api-production.s3.amazonaws.com%2Fuploads%2Fcard%2Fimage%2F638812%2F2f45c28e-a0d8-4e88-9d6f-396f27d2524e.jpg)